

A novel *LOXHD1* variant in a Chinese couple with hearing loss

Journal of International Medical Research

2019, Vol. 47(12) 6082–6090

© The Author(s) 2019

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/0300060519884197

journals.sagepub.com/home/imr



Chuan Zhang¹ , Shengju Hao¹, Yali Liu¹,
Bingbo Zhou¹, Furong Liu¹, Lei Zheng¹,
Panpan Ma¹, Qing Liu¹, Xiaojuan Lin¹,
Yousheng Yan^{2,*} and Qinghua Zhang^{1,*}

Abstract

Objective: To perform molecular diagnosis and genetic counseling in a young Chinese couple with congenital hearing loss.

Methods: Variant screening analysis was performed by PCR and direct Sanger sequencing or targeted next-generation sequencing of all known hearing loss genes. Novel variants were evaluated by PolyPhen2 and PROVEAN software tools to evaluate possible effects on protein function.

Results: We identified causative variants in the young couple: c.235delC (rs80338943)/c.299-300delAT (rs111033204) compound heterozygous variants of *GJB2* in the husband and c.1828G>A (p.Glu610Lys, rs535637788)/c.2825-2827delAGA compound heterozygous variants of *LOXHD1* in the wife. The *LOXHD1* c.1828G>A variant has only previously been reported in a Mexican-American individual in the 1000 Genomes Project database. Using PolyPhen2 and PROVEAN, we speculated that the *LOXHD1* variant c.1828G>A is potentially pathogenic.

Conclusion: We carried out molecular diagnosis in a young couple with congenital hearing loss, and identified different disease-causing genes in the two individuals. The *LOXHD1* variant c.1828G>A present in the wife had not previously been reported in individuals with congenital hearing loss. We determined this to be a potential pathogenic variant, and a novel variant associated with hearing loss in a Chinese individual.

*These authors contributed equally to this work.

Corresponding author:

Qinghua Zhang, Gansu Provincial Maternal and Child Health Care Hospital, Gansu Provincial Key Laboratory of Birth Defects Prevention and Control, Lanzhou, Gansu 730050, China.

Email: zhangchuan0404@163.com

¹Gansu Provincial Maternal and Child Health Care Hospital, Gansu Provincial Key Laboratory of Birth Defects Prevention and Control, Lanzhou, Gansu, China

²National Research Institute for Family Planning, Beijing, China



Keywords

Hearing loss, *LOXHD1*, *DFNB77*, Sanger sequencing, next-generation sequencing, genetic counseling

Date received: 12 March 2019; accepted: 2 October 2019

Introduction

Hearing loss (HL) is the most frequent sensory deficit in humans, with a prevalence of around 1/1000 in newborns.^{1,2} Approximately 50% to 60% of hearing loss cases are caused by genetic factors.³ The genetic mode of HL inheritance can be autosomal recessive, autosomal dominant, mitochondrial, or X/Y-linked. To date, 121 genes have been reported to be associated with hearing loss (<http://hereditaryhearingloss.org/>): 45 are autosomal dominant genes, 71 are autosomal recessive, and 5 are X-linked. However, most of these genes have only been reported in one or a few families.⁴ Epidemiological studies showed that variants in *GJB2*, *SLC26A4*, and 12S rRNA genes are highly correlated with hereditary HL.² The most frequent genetic cause of HL is variants in *GJB2*, and most of these cases occur with non-progressive HL. Variants in *SLC26A4*, *CDH23*, and *MYO3A* were also shown to be associated with naturally occurring progressive HL.^{5,6}

The genetic diagnosis of HL is very important because the findings can be used to aid treatment decisions, and provide prognostic information and genetic counseling for the patient's family.⁷ Here, we describe a young couple with HL in whom the husband carried compound heterozygous variants of *GJB2*, and the wife had an extremely rare form of deafness and compound heterozygous variants of *LOXHD1*. We provided genetic counseling for this couple and followed them up during their pregnancy.

Patients and methods

Study population

We recruited a young Chinese couple (husband: 27 years old; wife: 25 years old) with congenital HL and 100 healthy controls (aged 25–30 years) from Gansu Provincial Maternal and Child Health Care Hospital. The couple had been married for 6 months and requested pre-pregnancy genetic counseling. The study was in accordance with the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Gansu Provincial Maternal and Child Health Care Hospital. Written informed consent was obtained from all participants.

Sample collection and genomic DNA preparation

Blood samples (2–3 mL) were collected from the probands and their parents and control individuals. Genomic DNA was extracted using a Tiangen DNA extraction kit (Tiangen Biotech, Beijing, China) according to the manufacturer's instructions and quantified spectrophotometrically.

Targeted next-generation sequencing (NGS) and Sanger sequencing

First, the coding exon and flanking sequences of *GJB2* were screened by PCR and direct sequencing using primers and conditions described in Table 1. If no *GJB2* variant was found, targeted capture of candidate disease genes ($n = 165$, Table 2) was performed using a GenCap custom

Table 1. Primers and PCR conditions for *GJB2* and *LOXHD1*.

Primer name	Sequence (5'–3')	Product size (bp)	Amplification reaction conditions
GJB2-F	CATGCTTGCTTACCCAGACTCA	873	95°C for 5 minutes, then 20 cycles of 94°C for 30 seconds, 62°C for 45 seconds, and 72°C for 1 minute 95°C for 5 minutes, then 15 cycles of 94°C for 30 seconds, 58°C for 45 seconds, and 72°C for 1 minute.
GJB2-R	TAGCGACTGAGCCTTGACAGC		
GJB2-S1	TGGGTTTTGATCTCCTCGATG	Sequencing primers	
GJB2-S2	GCCTACCGGAGACATGAGAAG		
LOXHD1-E14F	GGTAGTAGGGCTGGGTCTTCC	355	
LOXHD1-E14R	AGTTGCCTAACCCATCAGCTC		
LOXHD1-E19F	CACCAACTCCACGACAAGTTC	594	
LOXHD1-E19R	GAGGTGGTGGAAAGGATCTGAG		

GJB2-S1 and GJB2-S2 are the sequencing primers for *GJB2*.

Table 2. Genes in the hearing loss panel.

Nuclear genes associated with hereditary HL						
<i>ACTG1</i>	<i>ADGRV1</i>	<i>ALX3</i>	<i>BSND</i>	<i>CABP2</i>	<i>CCDC50</i>	<i>CDH23</i>
<i>CEACAM16</i>	<i>CHD7</i>	<i>CIB2</i>	<i>CLDN14</i>	<i>CLPP</i>	<i>CLRN1</i>	<i>COCH</i>
<i>COL11A1</i>	<i>COL11A2</i>	<i>COL1A1</i>	<i>COL1A2</i>	<i>COL2A1</i>	<i>COL4A3</i>	<i>COL4A4</i>
<i>COL4A5</i>	<i>COL4A6</i>	<i>COL9A1</i>	<i>COL9A2</i>	<i>CRYM</i>	<i>DFNB59</i>	<i>DIABLO</i>
<i>DIAPH1</i>	<i>DIAPH3</i>	<i>DSPP</i>	<i>ECM1</i>	<i>EDN3</i>	<i>EDNRB</i>	<i>ELMOD3</i>
<i>ESPN</i>	<i>ESRRB</i>	<i>EYA1</i>	<i>EYA4</i>	<i>FGF3</i>	<i>FGF8</i>	<i>FGFR1</i>
<i>FGFR3</i>	<i>FLNA</i>	<i>FOXO1</i>	<i>FREM1</i>	<i>FXN</i>	<i>GATA3</i>	<i>GIPC3</i>
<i>GJB1</i>	<i>GJB2</i>	<i>GJB3</i>	<i>GJB6</i>	<i>GLYAT</i>	<i>GPSM2</i>	<i>GRHL2</i>
<i>GRXCR1</i>	<i>GSDME</i>	<i>HARS</i>	<i>HARS2</i>	<i>HGF</i>	<i>HMX1</i>	<i>HOXA2</i>
<i>HSD17B4</i>	<i>IL13</i>	<i>ILDRI</i>	<i>KARS</i>	<i>KCNE1</i>	<i>KCNJ10</i>	<i>KCNQ1</i>
<i>KCNQ4</i>	<i>KITLG</i>	<i>KRT9</i>	<i>LAMA3</i>	<i>LARS2</i>	<i>LHFPL5</i>	<i>LOXHD1</i>
<i>LRTOMT</i>	<i>MARVELD2</i>	<i>MIR96</i>	<i>MITF</i>	<i>MPZ</i>	<i>MSRB3</i>	<i>MYH14</i>
<i>MYH9</i>	<i>MYO15A</i>	<i>MYO1A</i>	<i>MYO1E</i>	<i>MYO3A</i>	<i>MYO6</i>	<i>MYO7A</i>
<i>NDP</i>	<i>NDRG1</i>	<i>NEFL</i>	<i>NELL2</i>	<i>NF2</i>	<i>OPA1</i>	<i>OTOA</i>
<i>OTOF</i>	<i>OTOG</i>	<i>OTOGL</i>	<i>P2RX2</i>	<i>PABPN1</i>	<i>PAX3</i>	<i>PCDH15</i>
<i>PCDH9</i>	<i>PDZD7</i>	<i>PMP22</i>	<i>PNPT1</i>	<i>POLR1C</i>	<i>POLR1D</i>	<i>POU3F4</i>
<i>POU4F3</i>	<i>PROK2</i>	<i>PROKR2</i>	<i>PRPS1</i>	<i>PTPN11</i>	<i>PTPRQ</i>	<i>PTPRR</i>
<i>RDX</i>	<i>RPGR</i>	<i>SALL1</i>	<i>SALL4</i>	<i>SEC23A</i>	<i>SEMA3E</i>	<i>SERPINB6</i>
<i>SIX1</i>	<i>SIX5</i>	<i>SLC17A8</i>	<i>SLC19A2</i>	<i>SLC26A4</i>	<i>SLC26A5</i>	<i>SMAD4</i>
<i>SMPX</i>	<i>SNAI2</i>	<i>SOX10</i>	<i>STRC</i>	<i>TBC1D24</i>	<i>TCIRG1</i>	<i>TCOF1</i>
<i>TECTA</i>	<i>TIMM8A</i>	<i>TJP2</i>	<i>TMCI</i>	<i>TMEM126A</i>	<i>TMIE</i>	<i>TMPRSS3</i>
<i>TMPRSS4</i>	<i>TNC</i>	<i>TPRN</i>	<i>TRIOBP</i>	<i>TRMU</i>	<i>TSPEAR</i>	<i>TYR</i>
<i>USH1C</i>	<i>USH1G</i>	<i>USH2A</i>	<i>WFS1</i>	<i>WHRN</i>		
Mitochondrial gene						
<i>MT-RNR1</i>	<i>RNR-TL1</i>	<i>MT-CO1</i>	<i>RNR-TS1</i>	<i>MT-TK</i>	<i>RNR-TE</i>	

enrichment kit (MyGenostics, Beijing, China). Briefly, 1 µg of DNA library was mixed with BL buffer and a GenCap hypercholesterolemia probe (MyGenostics) and heated in a PCR cycler at 95°C for 7 minutes then 65°C for 2 minutes. A total of 23 µL HY buffer (pre-warmed to 65°C; MyGenostics) was added and the mixture was incubated at 65°C for 22 hours for hybridization. MyOne beads (50 µL; Thermo Fisher Scientific Inc., Rockford, IL, USA) were washed three times in 500 µL binding buffer (1×) and re-suspended in 80 µL binding buffer (1×). Next, 64 µL binding buffer (2×) was added and the mixture was transferred into a tube containing 80 µL MyOne beads, and spun for 1 hour on a rotator. The beads were then washed once with WB1 buffer at room temperature for 15 minutes and three times with WB3 buffer at 65°C for 15 minutes. Elution buffer was used to elute the bound DNA, which was amplified as follows: 98°C for 30 seconds then 15 cycles of 98°C for 25 seconds, 65°C for 30 seconds, and 72°C for 30 seconds, followed by 72°C for 5 minutes. PCR products were purified using SPRI beads (Beckman Coulter Inc., Brea, CA, USA) following the manufacturer's protocol. Enrichment libraries were sequenced on an Illumina HiSeq 2000 sequencer (Illumina, San Diego, CA, USA) for 100-bp paired reads.

After sequencing, high-quality reads were retrieved by filtering out adaptors, low-quality reads, and short sequences (<40 bp). Data quality control standards were: 10× > 95%, depth = 200 ± 30. The SOAPaligner program (SOAP v2.21) was used to align clean read sequences to the human reference genome (UCSC Genome Browser hg19). After removing duplicates with Picard software (v1.119), single nucleotide polymorphisms (SNPs) were identified using SOAPsnp v1.03. Subsequently, reads were realigned to the reference

genome using the Burrows–Wheeler alignment program (0.7.12-r1044), and insertions or deletions (InDels) were detected by the HaplotypeCaller of GATK software (<https://software.broadinstitute.org/gatk/>, GATK-3.5) and filtered by VariantFiltration of GATK software. We annotated the identified SNPs and InDels using the Exome-assistant program. Short read alignment and candidate SNP and InDel validation were performed using MagicViewer.

We performed Sanger sequencing for all identified variants in the probands and their parents. PCR primers for Sanger sequencing were designed by Primer 3.0 software (<http://bioinfo.ut.ee/primer3-0.4.0/>). Primers and PCR conditions for *GJB2* and *LOXHD1* are shown in Table 1. DNA sequencing was performed on an ABI 3500DX Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

Bioinformatics analysis

If a novel variant was found that was not reported in the Human Gene Variant Database (<http://www.hgmd.cf.ac.uk/>) or ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>), we used PolyPhen2 (<http://genetics.bwh.harvard.edu/pph2>) and PROVEAN (<http://provean.jcvi.org/index.php>) tools to predict its possible functional role. To exclude the possibility that the variant was a polymorphism, we also performed direct sequencing in 100 healthy controls.

Results

Variant analysis

PCR and direct Sanger sequencing identified c.235delC (rs80338943)/c.299-300delAT (rs111033204) compound heterozygous variants of *GJB2* in the husband. c.235delC was inherited from his mother

and c.299-300delAT was inherited from his father (Figure 1).

No *GJB2* variants were identified in the wife, so targeted NGS was used to search for potential pathogenic variants. She was shown to carry c.1828G>A (p.Glu610Lys, rs535637788)/c.2825-2827delAGA compound heterozygous variants of *LOXHD1*, with c.2825-2827delAGA inherited from her mother and c.1828G>A from her father (Figure 2). Her hearing loss is an extremely rare form known as DFNB77 (OMIM: 613079). Variant c.2825-2827delAGA has previously been reported to be associated with DFNB77,⁷ but variant c.1828G>A (p.E610K) was only reported in a Mexican-American individual in the 1000 Genomes database. It has not been reported to be associated with DFNB77. PCR and direct Sanger sequencing did not

identify this variant in any of our 100 healthy controls.

Bioinformatics analysis score

PolyPhen2 and PROVEAN tools were used to evaluate the possible functional role of variant c.1828G>A. PolyPhen2 gave a score of 1, suggesting that the site might be a damaging variation. The PROVEAN score was -3.203, and the site was considered “deleterious”.

Pregnancy outcome

Following molecular analysis, we provided genetic counseling to the young couple with HL. We explained that their children were unlikely to have HL because they both carried different genetic variants. During their pregnancy, they underwent regular prenatal




Figure 1. Results of Sanger sequencing. Compound heterozygous variants were detected in the proband. c.235delC (rs80338943, left)/c.299-300delAT (rs111033204, right) of *GJB2*. The father carried the heterozygous variant c.299-300delAT, while the mother and fetus carried the heterozygous variant c.235delC.




Figure 2. Results of Sanger sequencing. Compound heterozygous variants were detected in the proband. c.1828G>A(p.Glu610Lys, rs535637788, left)/c.2825-2827delAGA (right) of *LOXHD1*. The father and fetus carried the heterozygous variant c.1828G>A, while the mother carried the heterozygous variant c.2825-2827delAGA.

checkups which detected the presence of the c.235delC *GJB2* variant and the c.1828G>A *LOXHD1* variant in the fetus (Figures 1 and 2). The baby was born in June 2018, and both ears passed the hearing screening test.

Discussion

We identified causative variants of HL in both individuals of a young Chinese couple. The variants of the husband were common and the c.2825-2827delAGA *LOXHD1* variant of the wife was previously associated with DFNB77; however, the c.1828G>A *LOXHD1* variant of the wife has only been reported in a Mexican-American individual in the 1000 Genomes database, and not in the HGMD database or elsewhere. PolyPhen2 and PROVEAN

tools suggested that it is a likely pathogenic variant.

LOXHD1 is located on chromosome 18q12-q21 and contains at least 43 exons.⁸ It encodes lipoygenase homology domain 1-containing protein 1 which has 15 PLAT domains⁴ that are involved in targeting proteins to the plasma membrane and mediating protein interactions.⁹⁻¹² Mouse studies showed that the *Loxhd1* product is localized to the stereocilia of sensory hair cells, and that *Loxhd1* variants can induce deafness with defects in the stereocilia followed by hair cell degeneration.¹³ This indicates that *LOXHD1* plays an important role in maintaining normal hair cell function.

Although DFNB77 has previously been associated with *LOXHD1* variants, it is a highly heterogeneous disease both phenotypically and genetically. More than

Table 3. Known *LOXHD1* variants causative of hearing loss.

No.	Nucleotide or amino acid change	Variant type	Zygoty	Type of HL	Progressiveness	Population
1 ⁵	c.879 + 1G>A	Splice	Hom	Profound	Non-progressive	Japanese
2 ⁵	c.5869G>T	Nonsense	Het	Moderate-severe	Non-progressive	Japanese
3 ⁵	c.4480C>T	Nonsense	Het	Moderate-severe	Non-progressive	Japanese
4 ⁷	c.884C>T	Missense	Het	Moderate-severe	Progressive	–
5 ⁷	c.2825_2827delAGA	Frameshift	Het	Moderate-severe	Progressive	–
6 ⁷	c.2797C>T	Nonsense	Het	Profound	Non-progressive	–
7 ⁷	c.1730T>G	Frameshift	Het	Profound	Non-progressive	–
8 ⁷	c.2722G>A	Missense	Het	Profound	Non-progressive	–
9 ⁷	c.3015_3017delCTT	Frameshift	Het	Profound	Non-progressive	–
10 ⁷	c.766G>T	Nonsense	Het	Profound	Non-progressive	–
11 ⁷	c.3596T>C	Missense	Het	–	–	–
12 ⁷	c.2696G>C	Missense	Het	–	–	–
13 ⁷	c.4526G>A	Missense	Hom	Profound	Progressive	–
14 ⁷	c.4480C>T	Nonsense	Hom	Profound	Progressive	–
15 ⁷	c.3206G>A	Missense	Het	Moderate-severe	Non-progressive	–
16 ⁷	c.894T>G	Nonsense	Het	Moderate-severe	Non-progressive	–
17 ⁷	c.1501delG	Frameshift	Het	Profound	Progressive	–
18 ⁷	c.1193G>A	Missense	Het	Profound	Progressive	–
19 ⁷	c.1147C>T	Nonsense	Het	Profound	Progressive	–
20 ⁸	c.4714C>T	Nonsense	Hom	Profound	Non-progressive	Jewish
21 ⁹	c.5674G>T	Missense	Het	Moderate-severe	Non-progressive	Japanese
22 ⁹	c.4212 + 1G>A	Splice	Het	Moderate-severe	Non-progressive	Japanese
33 ¹³	c.2008C>T	Nonsense	Hom	Moderate-severe	Progressive	Iranian
24 ¹⁴	p.Gly398Glu	Missense	Het	Profound	Progressive	American
25 ¹⁴	p.Arg383X	Nonsense	Het	Profound	Progressive	American
26 ¹⁵	c.2863G>T	Nonsense	Hom	–	–	Turkey
27 ¹⁵	c.4480C>T	Nonsense	Hom	–	–	Turkey
28 ¹⁶	c.1588C>T	Nonsense	Hom	Profound	Progressive	Qatar
29 ¹⁷	c.71delT	Frameshift	Hom	–	–	Turkish
30 ¹⁸	c.3371G>A	Missense	Het	Profound	Non-progressive	Cameroonian
31 ¹⁸	c.3979T>A	Missense	Het	Profound	Non-progressive	Cameroonian
32 ¹⁹	c.1751C>T	Missense	Het	Moderate-severe	Progressive	Chinese
33 ¹⁹	c.5815G>A	Missense	Het	Moderate-severe	Progressive	Chinese
34 ²⁰	p.A1406V	Missense	Het	–	–	–
35 ²⁰	p.K148*	Nonsense	Het	–	–	–
36 ²¹	c.797 G > A	Missense	Het	–	–	Chinese
37 [*]	c.1828G>A	Missense	Het	Profound	Non-progressive	Chinese

References shown as superscript numbers in first column; * This study
Hom, homozygous; het, heterozygous

23 probands with DFNB77 have been reported worldwide on PubMed, and 37 different disease-causing variants have been identified (Table 3).^{5,7–21} Most of these probands come from Asia, suggesting

that it has a high incidence of DFNB77. They show different auditory characteristics and audiometric phenotypes, varying from mild to profound and from stable to progressive sensorineural HL.^{5,7–21} Animal

studies revealed that homozygous missense variants of *Loxhd1* induced profound deafness while homozygous nonsense variants caused progressive HL.¹³ However, Wesdorp et al.⁴ found that the type of variant (nonsense or missense) did not associate with HL severity, and that the combination of a nonsense and missense variant could cause different audiometric phenotypes. Such research is limited, so correlations between *LOXHD1* variants and phenotypic characteristics of HL remain unclear.

LOXHD1 variants have not only been linked to HL but are also associated with late-onset Fuchs corneal dystrophy (FCD), a genetic disorder of the corneal endothelium.²² A case-control study by Stehouwer et al.²³ reported a significant association between FCD and hearing disorders, but this should be investigated in larger sample sizes.²² We believe that it is important to check for ophthalmology disorders in patients with HL caused by *LOXHD1* variants; however, we found no FCD phenotype in the current proband with *LOXHD1* variants.

In conclusion, we carried out molecular diagnosis in a young couple with congenital HL and identified different disease-causing variants in the two individuals. The husband had compound heterozygous variants of *GJB2*, while the wife had the extremely rare HL known as DFNB77 and compound heterozygous variants of *LOXHD1*. We followed up the pregnancy outcome of this couple, and report that both ears of their baby passed the hearing screening test. To the best of our knowledge, this is the third case reported in Chinese individuals and the first in the northwest of the country. PCR and direct Sanger sequencing cannot provide effective detection of diseases caused by such rare variants. However, with the development of molecular diagnostic technology, the cost of tests is decreasing and NGS will become a more effective way of

providing accurate molecular diagnosis and genetic counseling for rare diseases.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This work was supported by the Gansu Natural Science Foundation (Grant Nos.: 18JR3RA036, 1606RJZA151), the Lanzhou Talent Innovation and Entrepreneurship Project (Grant No.: 2018-RC-95), and the National Population and Reproductive Health Science Data Center of the People's Republic of China (Grant No.: 2005DKA32408).

ORCID iD

Chuan Zhang  <https://orcid.org/0000-0002-4403-4830>

References

1. Fortnum HM, Summerfield AQ, Marshall DH, et al. Prevalence of permanent childhood hearing impairment in the United Kingdom and implications for universal neonatal hearing screening: questionnaire based ascertainment study. *BMJ* 2001; 323: 536–540.
2. Du W, Wang Q, Zhu Y, et al. Associations between *GJB2*, mitochondrial 12S rRNA, *SLC26A4* variants, and hearing loss among three ethnicities. *Biomed Res Int* 2014; 2014: 746838.
3. Nance WE, Lim BG and Dodson KM. Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. *J Clin Virol* 2006; 35: 221–225.
4. Wesdorp M, Schreur V, Beynon AJ, et al. Further audiovestibular characterization of DFNB77, caused by deleterious variants in *LOXHD1*, and investigation into the involvement of Fuchs corneal dystrophy. *Clin Genet* 2018; 94: 221–231.
5. Mori K, Moteki H, Kobayashi Y, et al. Variants in *LOXHD1* gene cause various

- types and severities of hearing loss. *Ann Otol Rhinol Laryngol* 2015; 124: 135S–141S.
6. Hilgert N, Smith R and Van Camp G. Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? *Mutat Res* 2009; 681: 189–196.
 7. Sloan-Heggen CM, Bierer AO, Shearer AE, et al. Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss. *Hum Genet* 2016; 135: 441–450.
 8. Edvardson S, Jalas C, Shaag A, et al. A deleterious variant in the LOXHD1 gene causes autosomal recessive hearing loss in Ashkenazi Jews. *Am J Med Genet A* 2011; 155A: 1170–1172.
 9. Minami SB, Mutai H, Namba K, et al. Clinical characteristics of a Japanese family with hearing loss accompanied by compound heterozygous variants in LOXHD1. *Auris Nasus Larynx* 2016; 43: 609–613.
 10. Bateman A and Sandford R. The PLAT domain: a new piece in the PKD1 puzzle. *Curr Biol* 1999; 9: R588–R590.
 11. Hu J and Barr MM. ATP-2 interacts with the PLAT domain of LOV-1 and is involved in *Caenorhabditis elegans* polycystin signaling. *Mol Biol Cell* 2005; 16: 458–469.
 12. Aleem AM, Jankun J, Dignam JD, et al. Human platelet 12-lipoxygenase, new findings about its activity, membrane binding and low-resolution structure. *J Mol Biol* 2008; 376: 193–209.
 13. Grillet N, Schwander M, Hildebrand MS, et al. Variants in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans. *Am J Hum Genet* 2009; 85: 328–337.
 14. Eppsteiner RW, Shearer AE, Hildebrand MS, et al. Prediction of cochlear implant performance by genetic variant: the spiral ganglion hypothesis. *Hear Res* 2012; 292: 51–58.
 15. Diaz-Horta O, Duman D, Foster J, et al. Whole-exome sequencing efficiently detects rare variants in autosomal recessive nonsyndromic hearing loss. *PLoS One* 2012; 7: e50628.
 16. Vozzi D, Morgan A, Vuckovic D, et al. Hereditary hearing loss: a 96 gene targeted sequencing protocol reveals novel alleles in a series of Italian and Qatari patients. *Gene* 2014; 542: 209–216.
 17. Atik T, Onay H, Aykut A, et al. Comprehensive analysis of deafness genes in families with autosomal recessive nonsyndromic hearing loss. *PLoS One* 2015; 10: e0142154.
 18. Lebeko K, Sloan-Heggen CM, Noubiap JJ, et al. Targeted genomic enrichment and massively parallel sequencing identifies novel nonsyndromic hearing impairment pathogenic variants in Cameroonian families. *Clin Genet* 2016; 90: 288–290.
 19. Hu S, Sun F, Zhang J, et al. Genetic etiology study of ten Chinese families with nonsyndromic hearing loss. *Neural Plast* 2018; 2018: 4920980.
 20. Posey JE, Harel T, Liu P, et al. Resolution of disease phenotypes resulting from multi-locus genomic variation. *N Engl J Med* 2017; 376: 21–31.
 21. He L, Pang X, Chen P, et al. Carrier resequencing reveals rare but benign variants in recessive deafness genes. *Sci Rep* 2017; 7: 11355.
 22. Riazuddin SA, Parker DS, McGlumphy EJ, et al. Variants in LOXHD1, a recessive-deafness locus, cause dominant late-onset Fuchs corneal dystrophy. *Am J Hum Genet* 2012; 90: 533–539.
 23. Stehouwer M, Bijlsma WR and Van der Lelij A. Hearing disability in patients with Fuchs' endothelial corneal dystrophy: unrecognized co-pathology? *Clin Ophthalmol* 2011; 5: 1297–1301.